Literature DB >> 29248461

Knockout of l-Histidine Decarboxylase Prevents Cholangiocyte Damage and Hepatic Fibrosis in Mice Subjected to High-Fat Diet Feeding via Disrupted Histamine/Leptin Signaling.

Lindsey Kennedy1, Laura Hargrove2, Jennifer Demieville3, Jennifer M Bailey4, Wasim Dar5, Kishore Polireddy4, Qingzheng Chen4, Moises I Nevah Rubin4, Amelia Sybenga6, Sharon DeMorrow7, Fanyin Meng8, Lindsey Stockton9, Gianfranco Alpini7, Heather Francis10.   

Abstract

Feeding a high-fat diet (HFD) coupled with sugar, mimicking a Western diet, causes fatty liver disease in mice. Histamine induces biliary proliferation and fibrosis and regulates leptin signaling. Wild-type (WT) and l-histidine decarboxylase (Hdc-/-) mice were fed a control diet or an HFD coupled with a high fructose corn syrup equivalent. Hematoxylin and eosin and Oil Red O staining were performed to determine steatosis. Biliary mass and cholangiocyte proliferation were evaluated by immunohistochemistry. Senescence and fibrosis were measured by quantitative PCR and immunohistochemistry. Hepatic stellate cell activation was detected by immunofluorescence. Histamine and leptin levels were measured by enzyme immunoassay. Leptin receptor (Ob-R) was evaluated by quantitative PCR. The HDC/histamine/histamine receptor axis, ductular reaction, and biliary senescence were evaluated in patients with nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, or end-stage liver disease. Hdc-/- HFD mice had increased steatosis compared with WT HFD mice. WT HFD mice had increased biliary mass, biliary proliferation, senescence, fibrosis, and hepatic stellate cell activation, which were reduced in Hdc-/- HFD mice. In Hdc-/- HFD mice, serum leptin levels increased, whereas biliary Ob-R expression decreased. Nonalcoholic steatohepatitis patients had increased HDC/histamine/histamine receptor signaling. Hdc-/- HFD mice are susceptible to obesity via dysregulated leptin/Ob-R signaling, whereas the lack of HDC protects from HFD-induced fibrosis and cholangiocyte damage. HDC/histamine/leptin signaling may be important in managing obesity-induced biliary damage.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29248461      PMCID: PMC5840487          DOI: 10.1016/j.ajpath.2017.11.016

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents.

Authors:  Lindsey L Kennedy; Laura A Hargrove; Allyson B Graf; Taylor C Francis; Kyle M Hodges; Quy P Nguyen; Yoshi Ueno; John F Greene; Fanyin Meng; Victoria D Huynh; Heather L Francis
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

2.  Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms.

Authors:  Heather L Francis; Sharon Demorrow; Antonio Franchitto; Julie K Venter; Romina A Mancinelli; Mellanie A White; Fanyin Meng; Yoshiyuki Ueno; Guido Carpino; Anastasia Renzi; Kimberly K Baker; Hannah E Shine; Taylor C Francis; Eugenio Gaudio; Gianfranco D Alpini; Paolo Onori
Journal:  Lab Invest       Date:  2011-11-07       Impact factor: 5.662

3.  Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.

Authors:  Hannah Jones; Laura Hargrove; Lindsey Kennedy; Fanyin Meng; Allyson Graf-Eaton; Jennifer Owens; Gianfranco Alpini; Christopher Johnson; Francesca Bernuzzi; Jennifer Demieville; Sharon DeMorrow; Pietro Invernizzi; Heather Francis
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

4.  Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡.

Authors:  Kelly McDaniel; Fanyin Meng; Nan Wu; Keisaku Sato; Julie Venter; Francesca Bernuzzi; Pietro Invernizzi; Tianhao Zhou; Konstantina Kyritsi; Ying Wan; Qiaobing Huang; Paolo Onori; Heather Francis; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Hepatology       Date:  2016-11-05       Impact factor: 17.425

5.  Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation.

Authors:  G Alpini; S S Glaser; Y Ueno; L Pham; P V Podila; A Caligiuri; G LeSage; N F LaRusso
Journal:  Am J Physiol       Date:  1998-04

6.  Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient KitW-sh mice.

Authors:  Laura Hargrove; Lindsey Kennedy; Jennifer Demieville; Hannah Jones; Fanyin Meng; Sharon DeMorrow; Walker Karstens; Taronish Madeka; John Greene; Heather Francis
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

7.  A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease.

Authors:  P Sorrentino; G Tarantino; A Perrella; P Micheli; O Perrella; P Conca
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

Review 8.  Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Yurie Soejima; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

9.  Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene.

Authors:  András K Fülöp; Anna Földes; Edit Buzás; Krisztina Hegyi; Ildikó H Miklós; László Romics; Monika Kleiber; András Nagy; András Falus; Krisztina J Kovács
Journal:  Endocrinology       Date:  2003-06-26       Impact factor: 4.736

10.  Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.

Authors:  Michal Ganz; Terence N Bukong; Timea Csak; Banishree Saha; Jin-Kyu Park; Aditya Ambade; Karen Kodys; Gyongyi Szabo
Journal:  J Transl Med       Date:  2015-06-16       Impact factor: 5.531

View more
  14 in total

1.  Prolonged intake of desloratadine: mesenteric lymphatic vessel dysfunction and development of obesity/metabolic syndrome.

Authors:  Olga Y Gasheva; Irina Tsoy Nizamutdinova; Laura Hargrove; Cassidy Gobbell; Maria Troyanova-Wood; Sally F Alpini; Sarit Pal; Christina Du; Angie R Hitt; Vlad V Yakovlev; M Karen Newell-Rogers; David C Zawieja; Cynthia J Meininger; Gianfranco D Alpini; Heather Francis; Anatoliy A Gashev
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-26       Impact factor: 4.052

2.  The Dynamic Interplay Between Mast Cells, Aging/Cellular Senescence, and Liver Disease.

Authors:  Debjyoti Kundu; Lindsey Kennedy; Vik Meadows; Leonardo Baiocchi; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2020-07-29

Review 3.  Mast cells in liver disease progression: An update on current studies and implications.

Authors:  Linh Pham; Lindsey Kennedy; Leonardo Baiocchi; Vik Meadows; Burcin Ekser; Debjyoti Kundu; Tianhao Zhou; Keisaku Sato; Shannon Glaser; Ludovica Ceci; Gianfranco Alpini; Heather Francis
Journal:  Hepatology       Date:  2021-12-12       Impact factor: 17.298

4.  Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2/ Mouse Model of Primary Sclerosing Cholangitis.

Authors:  Konstantina Kyritsi; Heather Francis; Tianhao Zhou; Ludovica Ceci; Nan Wu; Zhihong Yang; Fanyin Meng; Lixian Chen; Leonardo Baiocchi; Debjyoti Kundu; Lindsey Kennedy; Suthat Liangpunsakul; Chaodong Wu; Shannon Glaser; Gianfranco Alpini
Journal:  Gene Expr       Date:  2020-05-11

5.  Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis.

Authors:  Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Walker Karstens; Hannah Jones; Sharon DeMorrow; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Steven Smith; Austin Akers; Vik Meadows; Heather Francis
Journal:  Hepatology       Date:  2018-06-01       Impact factor: 17.425

6.  Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment.

Authors:  Lindsey Kennedy; Vik Meadows; Konstantina Kyritsi; Linh Pham; Debjyoti Kundu; Rewa Kulkarni; Karla Cerritos; Jennifer Demieville; Laura Hargrove; Shannon Glaser; Tianhao Zhou; Victoria Jaeger; Gianfranco Alpini; Heather Francis
Journal:  Am J Pathol       Date:  2020-03-03       Impact factor: 4.307

7.  Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice.

Authors:  Vik Meadows; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Fanyin Meng; Shohaib Virani; Evan Reinhart; Konstantina Kyritsi; Pietro Invernizzi; Zhihong Yang; Nan Wu; Suthat Liangpunsakul; Gianfranco Alpini; Heather Francis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-09-13       Impact factor: 5.187

8.  Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.

Authors:  Lixian Chen; Nan Wu; Shannon Glaser; Gianfranco Alpini; Lindsey Kennedy; Heather Francis; Ludovica Ceci; Tianhao Zhou; Niharika Samala; Konstantina Kyritsi; Chaodong Wu; Amelia Sybenga; Burcin Ekser; Wasim Dar; Constance Atkins; Vik Meadows
Journal:  Hepatology       Date:  2021-07-29       Impact factor: 17.298

9.  Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.

Authors:  Lindsey Kennedy; Vik Meadows; Amelia Sybenga; Jennifer Demieville; Lixian Chen; Laura Hargrove; Burcin Ekser; Wasim Dar; Ludovica Ceci; Debjyoti Kundu; Konstantina Kyritsi; Linh Pham; Tianhao Zhou; Shannon Glaser; Fanyin Meng; Gianfranco Alpini; Heather Francis
Journal:  Hepatology       Date:  2021-05-24       Impact factor: 17.298

10.  Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease.

Authors:  Amandeep Singh; Rajat Garg; Nan Lan; Mohamed Tausif Siddiqui; Mohit Gupta; Naim Alkhouri
Journal:  Indian J Gastroenterol       Date:  2020-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.